Works matching IS 13419625 AND DT 2023 AND VI 28 AND IP 10
Results: 14
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1237, doi. 10.1007/s10147-023-02397-9
- By:
- Publication type:
- Article
Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1411, doi. 10.1007/s10147-023-02393-z
- By:
- Publication type:
- Article
Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1421, doi. 10.1007/s10147-023-02392-0
- By:
- Publication type:
- Article
Clinical significance of metastatic tumor deposit foci in rectal cancer in the lateral pelvic lymph node area.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1388, doi. 10.1007/s10147-023-02391-1
- By:
- Publication type:
- Article
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1354, doi. 10.1007/s10147-023-02390-2
- By:
- Publication type:
- Article
Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1378, doi. 10.1007/s10147-023-02389-9
- By:
- Publication type:
- Article
Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1398, doi. 10.1007/s10147-023-02386-y
- By:
- Publication type:
- Article
Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1343, doi. 10.1007/s10147-023-02385-z
- By:
- Publication type:
- Article
Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1371, doi. 10.1007/s10147-023-02384-0
- By:
- Publication type:
- Article
Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1298, doi. 10.1007/s10147-023-02377-z
- By:
- Publication type:
- Article
Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1333, doi. 10.1007/s10147-023-02375-1
- By:
- Publication type:
- Article
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1259, doi. 10.1007/s10147-023-02372-4
- By:
- Publication type:
- Article
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1315, doi. 10.1007/s10147-023-02382-2
- By:
- Publication type:
- Article